The mTOR inhibitor Afinitor (everolimus) was approved in 2012 for metastatic HR-positive/HER-negative breast cancer in combination with an AI exemestane in patients whose cancer had progressed despite treatment with letrozole or anastrozole [44]. This evidence concerns the gene MTOR and cancer.